149 related articles for article (PubMed ID: 7879202)
1. Results of a 1-year randomized controlled trial with omega-3 fatty acid fish oil in renal transplantation under triple immunosuppressive therapy.
Maachi K; Berthoux P; Burgard G; Alamartine E; Berthoux F
Transplant Proc; 1995 Feb; 27(1):846-9. PubMed ID: 7879202
[No Abstract] [Full Text] [Related]
2. One-year randomized controlled trial with omega-3 fatty acid-fish oil in clinical renal transplantation.
Berthoux FC; Guerin C; Burgard G; Berthoux P; Alamartine E
Transplant Proc; 1992 Dec; 24(6):2578-82. PubMed ID: 1465872
[No Abstract] [Full Text] [Related]
3. Retrospective study of cyclosporine-prednisolone versus cyclosporine-azathioprine-prednisolone immunosuppression in living donor kidney transplantation.
Reissi D; Bardideh A; Samadzadeh B; Razi A
Transplant Proc; 1995 Oct; 27(5):2685-6. PubMed ID: 7482875
[No Abstract] [Full Text] [Related]
4. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine withdrawal improves long-term graft survival in renal transplantation.
Gallagher M; Jardine M; Perkovic V; Cass A; McDonald S; Petrie J; Eris J
Transplantation; 2009 Jun; 87(12):1877-83. PubMed ID: 19543068
[TBL] [Abstract][Full Text] [Related]
6. Living-related kidney transplantation using low-dose triple immunosuppression.
Rashid HU; Rahman M; Wahab MA; Kibria G; Rahman S; Jinnat S
Transplant Proc; 1994 Aug; 26(4):2089. PubMed ID: 8066680
[No Abstract] [Full Text] [Related]
7. Optimal combination of immunosuppressive agents for renal transplantation: first report of a multicentre, randomised trial comparing cyclosporine+prednisolone with cyclosporine+azathioprine and with triple therapy in cadaver renal transplantation. The Australian Collaborative Trials Committee.
Hardie IR; Tiller DJ; Mahony JF; Miach PJ; Thomson NM; Thatcher GN; Rigby RJ; Menzies BL
Transplant Proc; 1993 Feb; 25(1 Pt 1):583-4. PubMed ID: 8438424
[No Abstract] [Full Text] [Related]
8. Effect of hypertension, hyperlipidemia and cyclosporine A therapy on long-term renal allograft survival.
Maeda H; Sakamoto K; Kashiwabara H; Hachisu T; Yamada H; Matsushita K; Yamada K; Yokoyama T
Transplant Proc; 1996 Jun; 28(3):1633-4. PubMed ID: 8658816
[No Abstract] [Full Text] [Related]
9. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
Kitabayashi K; Munn SR; Sterioff S
Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
[No Abstract] [Full Text] [Related]
10. Conversion of cyclosporine to azathroprine in renal transplant recipients.
Bassiri A; Amiranssari B; Gol S
Transplant Proc; 1995 Oct; 27(5):2691. PubMed ID: 7482877
[No Abstract] [Full Text] [Related]
11. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
[No Abstract] [Full Text] [Related]
12. High incidence of posttransplant diabetes mellitus in renal transplant recipients on triple-drug immunosuppression.
Sakhuja V; Sharma UK; Jha V; Minz M; Chugh KS
Transplant Proc; 1995 Oct; 27(5):2728-30. PubMed ID: 7482892
[No Abstract] [Full Text] [Related]
13. Protocol biopsies in stable renal transplant patients under triple immunosuppression: results at 6 months.
Rush DN; Jeffery JR; Gough J
Transplant Proc; 1994 Oct; 26(5):2576. PubMed ID: 7940797
[No Abstract] [Full Text] [Related]
14. Kidney transplantation in pediatric population.
Mota C; Henriques C; Sarmento M; Pereira E; Xavier E; Pereira M
Transplant Proc; 1994 Oct; 26(5):2768-70. PubMed ID: 7940872
[No Abstract] [Full Text] [Related]
15. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens.
Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684
[No Abstract] [Full Text] [Related]
16. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
[No Abstract] [Full Text] [Related]
17. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
Buchholz B; Korn A
Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
[No Abstract] [Full Text] [Related]
18. Acute rejection under triple immunosuppressive therapy does not increase the risk of late first cadaveric renal allograft loss.
Isoniemi H; Kyllönen L; Eklund B; Höckerstedt K; Salmela K; von Willebrand E; Ahonen J
Transplant Proc; 1995 Feb; 27(1):875-7. PubMed ID: 7879216
[No Abstract] [Full Text] [Related]
19. Results of clinical renal transplantation in 15 dogs using triple drug immunosuppressive therapy.
Gregory CR; Kyles AE; Bernsteen L; Mehl M
Vet Surg; 2006 Feb; 35(2):105-12. PubMed ID: 16472290
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin in a porcine renal transplant model.
Almond PS; Moss A; Nakhleh R; Melin M; Chen S; Salazar A; Shirabe K; Matas A
Transplant Proc; 1993 Feb; 25(1 Pt 1):716. PubMed ID: 8438452
[No Abstract] [Full Text] [Related]
[Next] [New Search]
